Skip to Content
Merck
CN
All Photos(1)

Documents

Y0000703

Moxifloxacin hydrochloride

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydropyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C21H24FN3O4· HCl
CAS Number:
186826-86-8
Molecular Weight:
437.89
Beilstein:
8377447
MDL number:
MFCD00949117
UNSPSC Code:
41116107
PubChem Substance ID:
329831106
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

moxifloxacin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Cl.COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc4C(=O)C(=CN(C5CC5)c14)C(O)=O

InChI

1S/C21H24FN3O4.ClH/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24;/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28);1H/t11-,16+;/m0./s1

InChI key

IDIIJJHBXUESQI-DFIJPDEKSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Moxifloxacin hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1448606

Moxifloxacin hydrochloride, United States Pharmacopeia (USP) Reference Standard

1448617

Moxifloxacin Related Compound A, United States Pharmacopeia (USP) Reference Standard

1448640

Moxifloxacin Related Compound D, United States Pharmacopeia (USP) Reference Standard

1448639

Moxifloxacin Related Compound C, United States Pharmacopeia (USP) Reference Standard

1448628

Moxifloxacin Related Compound B, United States Pharmacopeia (USP) Reference Standard

1448655

Moxifloxacin Related Compound E, United States Pharmacopeia (USP) Reference Standard

1448672

Moxifloxacin Related Compound G, United States Pharmacopeia (USP) Reference Standard

1448661

Moxifloxacin Related Compound F, United States Pharmacopeia (USP) Reference Standard

Y0002099

Moxifloxacin for peak identification A, European Pharmacopoeia (EP) Reference Standard

Y0002078

Moxifloxacin for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0002081

Moxifloxacin for peak identification B, European Pharmacopoeia (EP) Reference Standard

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302,H319,H412

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 3 - Eye Irrit. 2

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Cemile Banu Cosar et al.
European journal of ophthalmology, 24(3), 325-329 (2013-09-24)
To investigate refractive and visual outcomes and complications of the Supracor procedure to treat presbyopia. A total of 123 eyes from 68 presbyopic patients with hyperopia were enrolled in this prospective, nonrandomized, clinical trial. The Supracor procedure was performed using
Rohit Shetty et al.
BioMed research international, 2014, 340509-340509 (2014-10-11)
To report the profile of microbial keratitis occurring after corneal collagen cross-linking (CXL) in keratoconus patients. A retrospective analysis of 2350 patients (1715 conventional CXL, 310 transepithelial CXL, and 325 accelerated CXL) over 7 years (from January 2007 to January
Lingmin He et al.
JAMA ophthalmology, 133(1), 51-59 (2014-10-17)
Wavefront-guided (WFG) and wavefront-optimized (WFO) platforms for refractive surgery are designed for improved visual outcomes. It is unclear which treatment profile is superior for patients undergoing photorefractive keratectomy (PRK). To compare the safety, efficacy, predictability, stability, and higher-order aberrations in
Sumeet Khanduja et al.
Journal of glaucoma, 24(4), 267-271 (2013-01-23)
To evaluate the change in anterior chamber angle parameters after scleral buckling surgery using anterior segment optical coherence tomography (ASOCT). Fifty-five phakic eyes of 55 subjects undergoing scleral buckling with the placement of an encircling band for primary rhegmatogenous retinal
Lingmin He et al.
American journal of ophthalmology, 157(6), 1170-1178 (2014-02-25)
To compare the clinical outcomes of wavefront-guided and wavefront-optimized laser in situ keratomileusis (LASIK). Prospective, randomized, fellow-eye-controlled study. The setting was a single academic institution. The study population included 110 eyes of 55 patients with myopia with and without astigmatism.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service